Vemurafenib

Clinical Trials Overview

17 trials found
About Vemurafenib

Vemurafenib is an oral selective BRAF kinase inhibitor approved for treating metastatic colorectal cancer harboring the BRAF V600E mutation. This targeted therapy specifically addresses the oncogenic BRAF mutation found in approximately 8-10% of colorectal cancers, often used in combination with other agents like cetuximab or MEK inhibitors. Vemurafenib represents a precision medicine approach for CRC patients whose tumors carry this specific molecular alteration, particularly in cases where standard chemotherapy regimens have failed.

Category Targeted Therapy
Brand Name Zelboraf
Mechanism Vemurafenib selectively inhibits the mutated BRAF V600E protein kinase, which normally drives uncontrolled cell proliferation through constitutive activation of the MAP kinase pathway. By blocking this aberrant BRAF signaling, the drug helps restore normal cell cycle control and promotes cancer cell death in tumors dependent on this oncogenic driver mutation.
Efficacy Data by Mutation
Response rates and survival outcomes by patient molecular profile
BRAF V600E 2B
35%
ORR
4.4m
PFS
9.6m
OS
n=19
Sample
BRAF V600E 2B
4%
ORR
3.7m
PFS
7.1m
OS
n=27
Sample
BRAF V600E 2B
4%
ORR
3.7m
PFS
7.1m
OS
n=27
Sample
BRAF V600E 3
33.3%
ORR
3.5m
PFS
7.2m
OS
n=12
Sample
17
Total Trials
5
Recruiting
2
Active
9
Completed
4,235
Total Enrollment
17
Countries
Research trend for Vemurafenib
Number of trials started per year
2
13
2
14
1
15
1
17
2
18
1
20
2
21
2
22
2
23
1
24
1
25
Research has declined since peaking at 2 trials in 2013.
Active sites for Vemurafenib
Recruiting sites 17 countries
Phase:
NCT06763029 Phase 2 Recruiting 36 patients
Start: Feb 2025
End: Dec 2026
INTERVENTIONAL
Medications: Cetuximab Vemurafenib
Efficacy and safety of irinotecan liposomes combined with cetuximab + vermofenib in first-line failure of advanced RAS wild /BRAF mutated colorectal cancer, Exploratory analysis of biomarkers (including but not limited to ctDNA, immune microenvironme...
China
NCT06603376 Phase 2 Recruiting 75 patients
Start: Sep 2024
End: Dec 2026
INTERVENTIONAL
Based on the upstream signaling features of BRAFV600E and the bypass feedback mechanisms, considering the pro-apoptotic effects of chemotherapy and the synergistic effects of targeted therapy, previous IMPROVEMENT trial creatively explored a balanced...
China
NCT06008119 Phase 3 Recruiting 165 patients
Start: Oct 2023
End: Dec 2026
INTERVENTIONAL
Medications: Tunlametinib Vemurafenib
This is a multicenter, randomized, open-label, Phase 3 study
China
NCT05768178 Phase 2 Recruiting 30 patients
Start: Mar 2023
End: Oct 2029
INTERVENTIONAL
Medications: Cobimetinib Vemurafenib
This clinical trial is looking at a combination of drugs called vemurafenib and cobimetinib. Vemurafenib is approved as standard of care for adult patients with unresectable or metastatic melanoma. Cobimetinib is approved as standard of care in combi...
United Kingdom
NCT05525858 Not Applicable Recruiting 1,000 patients
Start: Sep 2022
End: Mar 2027
OBSERVATIONAL
A national, prospective, multi-center, open-label, multi-cohort study comprised of a framework to screen patients for actionable targets and evaluation of molecular profiling guided therapy recommended by MTB based on genomic alterations using target...
South Korea
NCT03155620 Phase 2 Active 1,377 patients
Start: Jul 2017
End: Jan 2027
INTERVENTIONAL
This phase II Pediatric MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following a...
United States, Australia, Canada, Puerto Rico
NCT02304809 Phase 2 Active 216 patients
Start: Oct 2014
End: Oct 2027
INTERVENTIONAL
Medications: Vemurafenib
Patients with metastatic or unresectable locally advanced malignancies harboring BRAF genomic alterations, the biological target of vemurafenib, and who are no more amenable to curative treatment. To explore the efficacy of vemurafenib as a single a...
France
NCT04831528 Not Applicable Not yet recruiting 100 patients
Start: Apr 2021
End: Jun 2026
OBSERVATIONAL
Medications: Bevacizumab Cetuximab Vemurafenib
This study aimis at detecting the genomic changes of ctDNA in patients of RAS and BRAF wild-type mCRC, who failed after first line treatment containing cetuximab. According to the results of ctDNA detection, individualized second-line targeted therap...
NCT05233332 Phase 2 Completed
Start: Feb 2022
End: Jul 2024
INTERVENTIONAL
Medications: Vemurafenib
The study consists of the two parts, phase IIa and phase IIb.
China
NCT05019534 Phase 1 Completed
Start: Aug 2021
End: Dec 2022
INTERVENTIONAL
BRAF mutation exists in about 10-12% of colorectal cancer, among which BRAF V600E mutation is the most common type, which is an important biomarker for predicting the prognosis and precise treatment efficacy of metastatic colorectal cancer (mCRC). Th...
China
NCT04790448 Phase 1 Completed 37 patients
Start: Jul 2020
End: Dec 2021
INTERVENTIONAL
Medications: Cetuximab Irinotecan Vemurafenib
This prospective, multicenter, single arm clinical trial was designed to evaluate the efficacy and safety of Vemurafenib in combination with Irinotecan and Cetuximab in the treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer.
China
NCT03727763 Phase 2 Completed
Start: Oct 2018
End: Dec 2022
INTERVENTIONAL
Medications: Cetuximab Irinotecan Vemurafenib
This clinical trial aims to evaluate the efficacy, safety of FOLFIRI with vemurafenib and cetuximab in Advanced Colorectal Cancer Patients with BRAF V600E mutation.
China
NCT05540951 Phase 3 Completed
Start: Jun 2018
End: Dec 2022
INTERVENTIONAL
In this study, we compared first-line VIC regimen with chemotherapy plus bevacizumab in Chinese patients with initially unresectable BRAF V600E-mutated mCRC. The principal goal was to evaluate the safety of VIC regimen, and to investigate the tumor r...
China
NCT02291289 Phase 2 Completed 1,044 patients
Start: Apr 2015
End: Mar 2021
INTERVENTIONAL
This randomized, multi-center, active-controlled, open-label, parallel-group study will investigate the efficacy and safety of biomarker-driven maintenance treatment for first-line mCRC. Participants with mCRC are eligible for entry and cannot have r...
Argentina, Belgium, Bosnia and Herzegovina, Brazil, Denmark, Egypt, France, Germany, Greece, Italy,
NCT02164916 Phase 2 Completed 106 patients
Start: Nov 2014
End: Nov 2020
INTERVENTIONAL
Medications: Cetuximab Vemurafenib
This randomized phase II trial studies how well irinotecan hydrochloride and cetuximab with or without vemurafenib works in treating patients with colorectal cancer that has spread to nearby tissue or lymph nodes, that has spread to other places in t...
United States
NCT01787500 Phase 1 Completed 33 patients
Start: Feb 2013
End: Mar 2026
INTERVENTIONAL
Medications: Cetuximab Vemurafenib
This phase I trial studies the side effects and best dose of vemurafenib when given together with cetuximab and irinotecan hydrochloride in treating patients with solid tumors that have spread to other parts of the body or cannot be removed by surger...
United States
NCT01791309 Phase 1 Completed 16 patients
Start: Jan 2013
End: Mar 2015
INTERVENTIONAL
Medications: Vemurafenib
The purpose of this study is to test a new drug combination consisting of two drugs, vemurafenib (also known as ZelborafTM) and panitumumab (also known as VectibixTM). This treatment is being tested in a subgroup of patients with colorectal cancer wh...
United States